| Intrinsic Valuation of: AJANTPHARM | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 74 | Market Cap | ₹321B | |||||
| 2021 | - | - (-) | P/E Ratio | 34 | Total Asset | ₹50B | |||||
| 2022 | ₹4B | - (-) | Net Income | ₹9B | Total Debt | ₹0 | |||||
| 2023 | ₹6B | 49.6% (32.5%) | EBITDA | ₹14B | Total Liab | ₹12B | |||||
| 2024 | ₹6B | 2.4% (-9.8%) | Opr Margin | 0.50 | Debt/Equity | - | |||||
| 2025 | ₹8B | 32.7% (20.1%) | PreTax Margin | 49.97 | BV/Share | 300 | |||||
| 5Y Average FCF | ₹6B | 28.2% (14.3%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (25.0%) | ||||||||||
| 2026 | ₹10B | MBG Intrinsic Value | ₹658 | ||||||||
| 2027 | ₹13B | ||||||||||
| 2028 | ₹16B | ||||||||||
| 2029 | ₹20B | ||||||||||
| 2030 | ₹26B | ||||||||||
| 2031 | ₹32B | ||||||||||
| Terminal Value | ₹666B | Net Worth/Share | ₹303 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹521B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹2B | ₹4,189 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹0 | WACC | 7.3% | 3,644 | 3,933 | 4,283 | 4,713 | 5,256 | |||
| Equity Value | ₹523B | 7.4% | 3,610 | 3,893 | 4,235 | 4,655 | 5,184 | ||||
| Shares Outstanding | 124,912,000 | 7.4% | 3,576 | 3,854 | 4,189 | 4,599 | 5,113 | ||||
| 7.9% | 3,269 | 3,499 | 3,770 | 4,097 | 4,498 | ||||||
| DCF Intrinsic Value | ₹4,189 | 8.4% | 3,007 | 3,199 | 3,423 | 3,689 | 4,008 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||